Tamoxifen Prevention Study Enrollment Nears Completion
BETHESDA, Md--The Breast Cancer Prevention Trial (BCPT), launched in 1992, will need fewer women than originally estimated for completion. Although planned for 16,000 women, the trial now has more than 12,000 enrolled, and needs only another 1,000 for completion, which is expected next year.
BETHESDA, Md--The Breast Cancer Prevention Trial (BCPT), launchedin 1992, will need fewer women than originally estimated for completion.Although planned for 16,000 women, the trial now has more than12,000 enrolled, and needs only another 1,000 for completion,which is expected next year.
The purpose of the trial, being conducted by the NCI-sponsoredNational Surgical Adjuvant Breast and Bowel Project (NSABP) isto determine whether tamoxifen (Nolvadex) can prevent breast cancerin women at increased risk of the disease.
Because women who have volunteered for the study have had a muchgreater underlying risk of breast cancer than anticipated, thestudy will be able to get the answers it needs with fewer volunteers.In addition, the women who have volunteered are so committed thatthey are not dropping out at the normal rate.
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
